Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Emtricitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 1.00 |
| ▸ | POLG | P54098 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.63 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.63 |
| ▸ | DCK | P27707 | 7/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emtricitabine, (+/-)- SCHEMBL122131 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL267686 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL3230512 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL12202574 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL5427218 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL6362885 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL3722124 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL39708 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL22413085 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL12662838 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20180105552-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | KU LEUVEN RESEARCH & DEVELOPMENT (BE) | 2018-04-19 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| EP-2322518-A1 | Method of manufacture of 1,3-dioxolane and 1,3-oxathiolane nucleosides | Gilead Sciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | ALB 1696/4885POLG 448/4885LMNA 2417/4885 |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | DCTD, MTAP, TYMP | ALB 2324/4885POLG 647/4885LMNA 3743/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | ALB 2686/4885POLG 788/4885LMNA 1285/4885 |
| US-20180105552-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | TYMP, MTAP, PNP | ALB 4022/4885POLG 843/4885LMNA 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.